The Library
Rituximab and memory antibody levels after desensitization
Tools
Tools
Tools
Edey, Matthew M. (2011) Rituximab and memory antibody levels after desensitization. Transplant International, Vol.24 (No.8). e67-e68. ISSN 09340874
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1432-2277.2011.01255.x
Abstract
The recent article by Rogers et al. [1] yields a valuable insight into antibody levels after desensitization and subsequent renal transplantation. [...]
| Item Type: | Journal Item |
|---|---|
| Subjects: | Q Science > QR Microbiology > QR180 Immunology R Medicine > RM Therapeutics. Pharmacology |
| Library of Congress Subject Headings (LCSH): | Rituximab, Plasmapheresis, Transplantation immunology, HLA histocompatibility antigens |
| Journal or Publication Title: | Transplant International |
| Publisher: | Wiley-Blackwell Publishing Ltd. |
| ISSN: | 09340874 |
| Date: | August 2011 |
| Volume: | Vol.24 |
| Number: | No.8 |
| Page Range: | e67-e68 |
| Identification Number: | 10.1111/j.1432-2277.2011.01255.x |
| Status: | Peer Reviewed |
| Publication Status: | Published |
| Access rights to Published version: | Restricted or Subscription Access |
| Description: | Letter to the editor |
| Version or Related Resource: | Response to: Rogers N. M. et al. (2011). Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transplant International, 24: 21. |
| References: | 1. Rogers NM, Eng HS, Yu R, et al. Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transplant Int 2011; 24: 21. 2. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3612. 3. Pondrom S. The AJT Report: news and issues that affect organ and tissue transplantation. Am J Transplant 2010; 10: 2. 4. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402. 5. Warren DS, Montgomery RA. Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010; 47: 257. 6. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann Intern Med 1991; 114: 924. 7. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibodymediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160. 8. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628. 9. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89. 10. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011; 15: e2. 11. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47: 187. |
| URI: | http://wrap.warwick.ac.uk/id/eprint/38714 |
Data sourced from Thomson Reuters' Web of Knowledge
Actions (login required)
 |
View Item |
